About Ocelot Bio
Ocelot Bio is a company based in San Diego (United States) founded in 2020 by Gebhard Neyer and Geoff Harris. It operates as a B2B. Ocelot Bio has raised $36 million across 1 funding round from investors including RA Capital, Venrock and Vivo Capital. Ocelot Bio operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Aperiam Bio and PolyPeptide, among others.
- Headquarter San Diego, United States
- Founders Gebhard Neyer, Geoff Harris
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$36 M (USD)
in 1 rounds
-
Latest Funding Round
$36 M (USD), Series A
Apr 13, 2021
-
Investors
RA Capital
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Ocelot Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Ocelot Bio
Ocelot Bio has successfully raised a total of $36M through 1 strategic funding round. The most recent funding activity was a Series A round of $36 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ocelot Bio
Ocelot Bio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, Venrock and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
|
Locked | Locked | Locked |
Investor details for Ocelot Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ocelot Bio
Investment portfolio details for Ocelot Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ocelot Bio
Detailed financials for Ocelot Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ocelot Bio Comparisons
Peer comparison for Ocelot Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ocelot Bio
Ocelot Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm, Aperiam Bio and PolyPeptide, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Industrial and therapeutic proteins are manufactured by Aperiam Bio.
|
|
| Locked | Locked | Locked |
Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs.
|
Detailed competitors of Ocelot Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ocelot Bio
Complete news archive for Ocelot Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ocelot Bio
Ocelot Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Ocelot Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Geoff Harris is the current CEO of Ocelot Bio. They have also founded this company.
Ocelot Bio is a funded company, having raised a total of $36M across 1 funding round to date.
Ocelot Bio operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, producing manufactured goods, and peptide production. Ocelot Bio is a CDMO specializing in peptide manufacturing services. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
Ocelot Bio's top competitors include Enzene Biosciences, Hybio Pharmaceutical and PolyPeptide.
Ocelot Bio has 3 investors. Key investors include RA Capital, Venrock, and Vivo Capital.